Abstract
Background
The aim of the study is to clarify if a classification based on the time of occurrence of associated malignancies in GIST patients can help in the understanding of the clinical controversies observed in these patients.
Methods
We retrospectively reviewed all the patients diagnosed with GIST tumors between January 1999 and October 2016. They were divided into GIST patients associated with other tumors (A-GIST) and those not associated (NA-GIST). A-GIST patients were also divided into four types according to the proposed classification.
Results
Of 104 GIST patients, 32 (30.7%) (A-GIST group) had at least one additional primary malignancy. The most frequent location of the associated malignancy was the GI tract (26%). Compared to NA-GIST, A-GIST were more often asymptomatic with a lower risk of recurrence. The main cause of death in NAGIST was GIST itself, being associated tumors the main cause of death in A-GIST group. No differences were found in DFS and OS between A-GIST and NA-GIST.
Conclusions
The use of the proposed classification classifies GIST patients with associated malignancies in different subtypes that differ substantially in terms of incidence, type of neoplasms associated, cause of the association and prognosis.
Similar content being viewed by others
References
Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438(1):1–12.
Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90.
Carney JA. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: a five-year review. Medicine (Baltimore). 1983;62(3):159–69.
Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology. 2001;120(1):210–5.
Burgoyne AM, Somaiah N, Sicklick JK. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol. 2014;26(4):408.
Giuliani J, Bonetti A. The occurrence of gastrointestinal stromal tumors and second malignancies. J Gastrointest Canc. 2015;46(4):408–12.
Agaimy A, Wünsch PH, Sobin LH, et al. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23(2):120–9.
Fernández Hernández JÁ, Olivares Ripoll V, Parrilla Paricio P. Asociación de tumores del estroma gastrointestinal con otros tumores primarios. Propuesta de una nueva clasificación. Med Clín. 2016;147(9):405–9.
Warren S. Multiple primary malignant tumors A survey of the literature and a statistical study. Am J Cancer. 1932;16:1358–414.
Feinstein AR, Bondy PK. A new staging system for cancer, and a re-appraisal of “early” treatment and “cure” by radical surgery. Trans Assoc Am Phys. 1967;80:111–22.
Sellers AH. The clinical classification of malignant tumours: the TNM system. Can Med Assoc J. 1971;105(8):836.
Cananzi FCM, Judson I, Lorenzi B, et al. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Eur J Surg Oncol. 2013;39(11):1171–8.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.
Kramer K, Wolf S, Mayer B, et al. Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia. 2015;17(1):134–40.
Rodriquenz MG, Rossi S, Ricci R, et al. Gastrointestinal stromal tumors (GISTs) and second malignancies. Medicine (Baltimore) [Internet]. 2016 Sep 23 [cited 2018 May 29];95(38). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044889/.
Vassos N, Agaimy A, Hohenberger W, Croner RS. Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: prognostic implications. Int J Surg. 2014;12(5):371–7.
Sevinc A, Seker M, Bilici A, et al. Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Hepatogastroenterology. 2011;58(107–108):824–30.
Yan Y, Li Z, Liu Y, Zhang L, Li J, Ji J. Coexistence of gastrointestinal stromal tumors and gastric adenocarcinomas. Tumor Biol. 2013;34(2):919–27.
Adim SB, Filiz G, Kanat O, Yerci O. Simultaneous occurrence of synchronous and metachronous tumors with gastrointestinal stromal tumors. Bratisl Lek Listy. 2011;112(11):623–5.
Gonçalves R, Linhares E, Albagli R, et al. Occurrence of other tumors in patients with GIST. Surg Oncol. 2010;19(4):e140–3.
Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010;21(10):2107–11.
Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang C-M, et al. Increased risk of additional cancers among patients with gastrointestinal stromal tumors: a population-based study. Cancer. 2015;121(17):2960–7.
Hechtman JF, DeMatteo R, Nafa K, et al. Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): a clinicopathologic study of 260 patients with molecular analysis and review of the literature. Ann Surg Oncol. 2015;22(8):2633–9.
Smith MJ, Smith HG, Mahar AL, et al. The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors. Int J Cancer. 2016;139(8):1744–51.
Du J, Shen N, He H-S, et al. Synchronous gastrointestinal cancer and gastrointestinal stromal tumors: a single-institution experience. World J Surg Oncol. 2016;14(1):130.
Karanikas M, Machairiotis N, Zarogoulidis P, et al. Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions. Onco Targets Ther. 2012;12(5):433–8.
Zhou Y, Wu X-D, Shi Q, Jia J. Coexistence of gastrointestinal stromal tumor, esophageal and gastric cardia carcinomas. World J Gastroenterol. 2013;19(12):2005–8.
Lin M, Lin J-X, Huang C-M, et al. Prognostic analysis of gastric gastrointestinal stromal tumor with synchronous gastric cancer. World J Surg Oncol. 2014;12(1):25.
Phan K, Martires K, Kurlander DE, et al. The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate. Trans Cancer Res. 2013;3(2):152–9.
Liszka Ł, Zielińska-Pająk E, Pająk J, et al. Coexistence of gastrointestinal stromal tumors with other neoplasms. J Gastroenterol. 2007;42(8):641–9.
Acknowledgements
The authors acknowledge the work of Galian MJ for her technical assistance in the preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have any financial disclosures to make regarding the eventual acceptance and publication of this study.
Ethical approval
This work has been approved by the ethics committee of the hospital.
Informed consent
The included patients have been informed and have consented to the use of their data anonymously for their scientific use.
Rights and permissions
About this article
Cite this article
Fernández, J.A., Olivares, V., Gómez-Ruiz, A.J. et al. Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification. Clin Transl Oncol 21, 646–655 (2019). https://doi.org/10.1007/s12094-018-1966-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-018-1966-5